Literature DB >> 32960646

Assessment, Diagnosis, and Treatment of Dysphagia in Patients Infected With SARS-CoV-2: A Review of the Literature and International Guidelines.

José Vergara1, Stacey A Skoretz2,3,4, Martin B Brodsky5,6,7, Anna Miles8, Susan E Langmore9, Sarah Wallace10,11, Jaishika Seedat12, Heather M Starmer13, Lee Bolton14, Pere Clavé15, Susana Vaz Freitas16,17,18, Hans Bogaardt19, Koichiro Matsuo20, Cinthia Madeira de Souza21, Lucia Figueiredo Mourão22.   

Abstract

Purpose Speech-language pathologists are playing a crucial role in the assessment and management of patients infected with severe acute respiratory syndrome coronavirus 2. Our goal was to synthesize peer-reviewed literature and association guidelines from around the world regarding dysphagia assessment and management for this specific population. Method A review of publications available in the PubMed database and official guidelines of international groups was performed on May 23, 2020. The information was synthesized and categorized into three content areas for swallowing: clinical evaluation, instrumental assessment, and rehabilitation. Results Five publications were identified in the PubMed database. Following title, abstract, and full-text review, only three publications met inclusion criteria: two reviews and one narrative report. Additionally, 19 international guidelines were reviewed. To assess swallowing, a modified clinical evaluation was recommended and only following a risk assessment. Instrumental assessments were often considered aerosol generating, especially transnasal procedures such as endoscopy and manometry. For this reason, many associations recommended that these examinations be performed only when essential and with appropriate personal protective equipment. Guidelines recommended that intervention should focus on compensatory strategies, including bolus modification, maneuvers/postural changes, and therapeutic exercises that can be conducted with physical distancing. Respiratory training devices were not recommended during rehabilitation. Conclusions International associations have provided extensive guidance regarding the level of risk related to the management of dysphagia in this population. To date, there are no scientific papers offering disease and/or recovery profiling for patients with dysphagia and coronavirus disease 2019. As a result, research in this area is urgently needed.

Entities:  

Mesh:

Year:  2020        PMID: 32960646     DOI: 10.1044/2020_AJSLP-20-00163

Source DB:  PubMed          Journal:  Am J Speech Lang Pathol        ISSN: 1058-0360            Impact factor:   2.408


  5 in total

1.  Aerosol-generating behaviours in speech pathology clinical practice: A systematic literature review.

Authors:  Antonia Margarita Chacon; Duy Duong Nguyen; Patricia McCabe; Catherine Madill
Journal:  PLoS One       Date:  2021-04-28       Impact factor: 3.240

Review 2.  An International Commentary on Dysphagia and Dysphonia During the COVID-19 Pandemic.

Authors:  Anna Miles; Jackie McRae; Gemma Clunie; Patricia Gillivan-Murphy; Yoko Inamoto; Hanneke Kalf; Mershen Pillay; Susan Pownall; Philippa Ratcliffe; Theresa Richard; Ursula Robinson; Sarah Wallace; Martin B Brodsky
Journal:  Dysphagia       Date:  2022-01-04       Impact factor: 2.733

3.  Letter to the Editor regarding "Dysphagia in non-intubated patients affected by COVID-19 infection".

Authors:  Max Sarmet; Alessandra Dorça; Jorge L Zeredo; Antonio M Esquinas
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-09-24       Impact factor: 2.503

4.  Speech-language pathology approaches to neurorehabilitation in acute care during COVID-19: Capitalizing on neuroplasticity.

Authors:  Nicole Langton-Frost; Martin B Brodsky
Journal:  PM R       Date:  2021-11-25       Impact factor: 2.218

Review 5.  Providing rehabilitation to patients recovering from COVID-19: A scoping review.

Authors:  Marina B Wasilewski; Stephanie R Cimino; Kristina M Kokorelias; Robert Simpson; Sander L Hitzig; Lawrence Robinson
Journal:  PM R       Date:  2021-10-07       Impact factor: 2.218

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.